Page 21 - Program Updates News Today

Eiger BioPharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update - Phase 3 HDV D-LIVR (Lonafarnib) 75% Enrolled; Full Enrollment Planned in 2021 - Phase 3 HDV LIMT-2 (Lambda) to Initiate in 2021 - Phase 3 COVID-19 TOGETHER Platform Study to Include Lambda Arm - $3.6M U.S. Zokinvy® Net Sales in Q1 2021 News provided by Share this article Share this article PALO ALTO, Calif., May 6, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial...

Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022 Positive data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic retinitis pigmentosa, with plans to advance the program into two pivotal Phase 2/3 trials before year end Exclusive worldwide license and discovery collaboration for non-ophthalmic target with Yarrow Biotechnology, an RTW Investments, LP incubated company Strengthened bala...

Binance May Add Stock Tokens Coinbase (COIN), after Tesla (TSLA), Also Reports Record-Breaking BNB Token Burn Leading crypto exchange Binance notes in its weekly report that it completed a record-breaking Binance Coin (BNB) token burn. The weekly report (April 10 – 16, 2021) from Binance reveals that the digital assets firm burned “a record $593 million in BNB.” The digital currency platform also introduced stock tokens. As mentioned in the update from Binance: “Record-breaking BNB bur...

To print this article, all you need is to be registered or login on Mondaq.com. On March 9, 2021, Mayor Bill de Blasio announced a series of proposed citywide zoning text amendments intended to incentivize the creation of local grocery stores, boost transit station accessibility, and ease administrative burdens for gyms and restaurants. The proposed zoning changes are expected to enter the citys public review process this spring or summer, which could put them on track t...

Poseida Therapeutics Reports Program Updates and Financial Results for the Fourth Quarter and Full Year 2020 News provided by Share this article Share this article SAN DIEGO, March 11, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced program updates and financial results for the fourth quarter a...

Share this article LA JOLLA, Calif., March 9, 2021 /PRNewswire/ --  Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the fourth quarter and year ended December 31, 2020 and provided a corporate update.  "Regulus finished the year on a high note", stated Jay Hagan, CEO of Regulus. "We advanced RGLS4326 into a Phase 1b stu...

Share this article Share this article PLYMOUTH MEETING, Pa., March 1, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today reported financial results for the quarter ended December 31, 2020. INOVIOs management will host a live conference call and webcast at 4:30 p.m. Eastern Standard Time today to discuss financial...

ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results Phase 2/3 pivotal Brighten pediatric trial of sepofarsen to begin in 2021; additional data from Phase 1/2 InSight extension study to be reported in H2 2021 QR-421a Stellar Phase 1/2 trial for Usher syndrome and non-syndromic retinitis pigmentosa interim analysis on track for late Q1/early Q2 2021 Further pi...

Share this article Share this article PERTH, Australia and NEW YORK, Feb. 22, 2021 /PRNewswire/ -- PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced updates to its programs and outlined its 2021-2022 corporate objectives. PYC is initially targeting inherited ocular diseases, for which it has three preclinical candidates in development. "This year we are focused ...

Lead program ORIC-101 continues patient enrollment investigating two therapeutic mechanisms of action and on track for two initial data readouts in ...